©The Author(s) 2026.
World J Gastroenterol. Feb 14, 2026; 32(6): 115556
Published online Feb 14, 2026. doi: 10.3748/wjg.v32.i6.115556
Published online Feb 14, 2026. doi: 10.3748/wjg.v32.i6.115556
Table 4 Adverse treatment reaction to hyperthermic intraperitoneal chemotherapy
| Number | Percentage (%) | |
| Intra-abdominal infection | 5 | 5.21 |
| Intra-abdominal hemorrhage | 1 | 1.04 |
| Abdominal pain | 5 | 5.21 |
| Nausea and vomiting | 23 | 23.96 |
| Diarrhea | 3 | 3.13 |
| Poor appetite and fatigue | 3 | 3.13 |
| Intestinal obstruction | 3 | 3.13 |
- Citation: Lian WL, Cai LS, Lian MQ, Lian MJ, Sun YQ, Lv CB, Huang GP, Huang RJ, Zhang YB, Zeng WM, Xu QH, Zhu QJ, Chen QX. Efficacy and safety of sequential hyperthermic intraperitoneal chemotherapy following surgery for pathological T staging 4 gastric cancer. World J Gastroenterol 2026; 32(6): 115556
- URL: https://www.wjgnet.com/1007-9327/full/v32/i6/115556.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i6.115556